Stocktoria
RECURSION PHARMACEUTICALS, INC. RXRX
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-04-16
RECURSION PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M | $4.0M |
| R&D expense | $475.3M | $314.4M | $241.2M | $155.7M | $135.3M | $63.3M |
| Operating income | -$648.1M | -$479.0M | -$350.1M | -$245.7M | -$182.8M | -$84.6M |
| Interest expense | — | — | $97,000 | $55,000 | $3.0M | $1.4M |
| Income tax | -$136,000 | -$1.1M | -$4.1M | $0 | $0 | $0 |
| Net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M | -$186.5M | -$87.0M |
| EPS (diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 | $-3.99 |
| Operating cash flow | -$371.8M | -$359.2M | -$287.8M | -$83.5M | -$158.6M | -$45.4M |
| Free cash flow | -$378.3M | -$372.9M | -$299.7M | -$120.6M | -$198.4M | -$51.2M |
| Cash & equivalents | $743.3M | $594.4M | $391.6M | $549.9M | $285.1M | $262.1M |
| Total assets | $1.5B | $1.4B | $653.7M | $701.3M | $610.3M | $298.6M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M | $56.6M |
| Shareholders' equity | $1.1B | $1.0B | $463.4M | $485.8M | $542.9M | -$206.3M |
Growth · year-over-year · Revenue CAGR 79.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +26.9% | +32.0% | +11.9% | +291.5% | +156.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.